BACKGROUND: The role of temporary ovarian suppression with luteinizing hormone-releasing hormone agonists (LHRHa) in the prevention of chemotherapy-induced @entity11157 ( @entity11157 ) is still controversial. Our meta-analysis of randomized, controlled trials (RCTs) investigates whether the use of LHRHa during chemotherapy in @entity0 @entity1 reduces treatment-related @entity11157 rate, increases pregnancy rate, and impacts disease-free survival (DFS). METHODS: A literature search using PubMed, Embase, and the Cochrane Library, and the proceedings of major conferences, was conducted up to 30 April 2015. Odds ratios (ORs) and 95% confidence intervals (CIs) for @entity11157 (i.e. @entity11157 by study definition, and @entity11157 defined as @entity2588 1 year after chemotherapy completion) and for @entity1 with pregnancy, as well hazard ratios (HRs) and 95% CI for DFS, were calculated for each trial. Pooled analysis was carried out using the fixed- and random-effects models. RESULTS: A total of 12 RCTs were eligible including 1231 @entity0 @entity1 . The use of LHRHa was associated with a significant reduced risk of @entity11157 (OR 0.36, 95% CI 0.23-0.57; P < 0.001), yet with significant heterogeneity (I(2) = 47.1%, Pheterogeneity = 0.026). In eight studies reporting @entity2588 rates 1 year after chemotherapy completion, the addition of LHRHa reduced the risk of @entity11157 (OR 0.55, 95% CI 0.41-0.73, P < 0.001) without heterogeneity (I(2) = 0.0%, Pheterogeneity = 0.936). In five studies reporting pregnancies, more @entity1 treated with LHRHa achieved pregnancy (33 versus 19 @entity1 ; OR 1.83, 95% CI 1.02-3.28, P = 0.041; I(2) = 0.0%, Pheterogeneity = 0.629). In three studies reporting DFS, no difference was observed (HR 1.00, 95% CI 0.49-2.04, P = 0.939; I(2) = 68.0%, Pheterogeneity = 0.044). CONCLUSION: Temporary ovarian suppression with LHRHa in young @entity0 @entity1 is associated with a reduced risk of chemotherapy-induced @entity11157 and seems to increase the pregnancy rate, without an apparent negative consequence on prognosis.

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of XXXX @entity1 : a meta-analysis of randomized studies.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity11157 :: ('MESH:D016649', 'Disease') :: ['POF', 'premature ovarian failure'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'premenopausal breast cancer']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
